Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Tarsus Pharmaceuticals has a consensus analyst rating of “Moderate Buy” from nine covering analysts, with an average 1-year price target of about $90.67.
• The company recently reported Q1 earnings of -$0.16 per share, beating expectations of -$0.40, and posted $162.05 million in revenue, above the consensus estimate of $149.60 million.
• Shares were trading around $58.93, while insiders sold stock in the recent quarter and institutional investors now hold about 90.01% of the company.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $90.6667.

A number of equities research analysts have commented on the company. Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, April 18th. Lifesci Capital raised Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Monday, March 16th. HC Wainwright reissued a "buy" rating and issued a $88.00 target price on shares of Tarsus Pharmaceuticals in a report on Monday, May 4th. Oppenheimer started coverage on Tarsus Pharmaceuticals in a report on Friday, April 24th. They issued an "outperform" rating and a $98.00 target price for the company. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $68.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th.

Tarsus Pharmaceuticals Stock Down 0.8%

Shares of Tarsus Pharmaceuticals stock opened at $58.93 on Tuesday. The company has a market cap of $2.54 billion, a P/E ratio of -51.69 and a beta of 0.49. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74. Tarsus Pharmaceuticals has a one year low of $38.51 and a one year high of $85.25. The firm has a fifty day moving average of $65.10 and a two-hundred day moving average of $70.94.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The company had revenue of $162.05 million during the quarter, compared to the consensus estimate of $149.60 million. On average, analysts forecast that Tarsus Pharmaceuticals will post -0.59 earnings per share for the current year.

Insider Transactions at Tarsus Pharmaceuticals

In related news, insider Dianne C. Whitfield sold 4,174 shares of the business's stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $279,658.00. Following the completion of the transaction, the insider owned 35,028 shares of the company's stock, valued at approximately $2,346,876. The trade was a 10.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bobak R. Azamian sold 11,964 shares of the business's stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $801,588.00. Following the completion of the transaction, the chief executive officer directly owned 33,421 shares of the company's stock, valued at $2,239,207. The trade was a 26.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 79,391 shares of company stock worth $5,432,035. Corporate insiders own 9.64% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TARS. Parallel Advisors LLC raised its stake in Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company's stock valued at $35,000 after purchasing an additional 291 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Tarsus Pharmaceuticals by 367.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 710 shares of the company's stock valued at $50,000 after purchasing an additional 558 shares during the last quarter. Comerica Bank raised its stake in Tarsus Pharmaceuticals by 470.0% in the 4th quarter. Comerica Bank now owns 855 shares of the company's stock valued at $70,000 after purchasing an additional 705 shares during the last quarter. Truvestments Capital LLC raised its stake in Tarsus Pharmaceuticals by 106.1% in the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company's stock valued at $74,000 after purchasing an additional 468 shares during the last quarter. Finally, Rockefeller Capital Management L.P. raised its stake in Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company's stock valued at $105,000 after purchasing an additional 172 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.